MEDI 212 |
| When Miguel Ondetti and David Cushman invented captopril, the first orally active angiotensin-converting enzyme (ACE) inhibitor, they demonstrated the power of understanding the detailed interaction of drugs with molecular targets. Their design hypothesis, developed without the benefit of protein sequence and three-dimensional structure that are routinely available today, guided the design of every subsequent ACE inhibitor and heralded the onset of the most productive era in the history of medicinal chemistry. The clinical introduction of ACE inhibitors transformed cardiovascular medicine and eased the suffering of millions. These events can now be reviewed in light of newly-available structural information on ACE and deeper insight into the role of the renin-angiotensin system. |
|
Heroes of Chemistry
1:30 PM-5:00 PM, Monday, August 20, 2007 BCEC -- 210 B/C, Oral
Division of Medicinal Chemistry |